Reports
Global Conjugate Vaccine Market: By Type: Monovalent Conjugate Vaccine, Multivalent Conjugate Vaccine; By Disease Indication; By Pathogen Type; By Patient; Regional Analysis; Historical Market and Forecast (2018-2028); Market Dynamics: SWOT Analysis, Porter’s Five Forces Analysis; Competitive Landscape; Industry Events and Developments
Global Conjugate Vaccine Market Outlook
The global conjugate vaccine market attained a value of more than USD 14.4 billion in 2021. The market is further expected to grow in the forecast period of 2023-2028 at a CAGR of 11% to reach over USD 27 billion by 2027.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Favourable Initiatives by Governments and Organisations Across the Globe Augmenting the Market Growth
The governments of various countries are introducing favourable schemes and programs to accelerate and promote conjugate vaccination in their countries. This is also propelling the market growth. For instance, the Indian government rolled out an anti-pneumonia vaccine as a part of its Universal Immunisation Program. Moreover, countries like the Democratic Republic of Congo, Pakistan, and Nigeria account for the highest death rate of people with pneumonia under the age of five years. Hence, various non-profit organisations are rolling out vaccination drives while raising awareness regarding preventable diseases in the regions. This is anticipated to fuel the market growth for conjugate vaccine.
Pneumonia is one of the dominant causes of child death worldwide. The rising demand to prevent pneumonia and acute respiratory infections is aiding the market growth. Various benefits associated with conjugate vaccines are also increasing their use. They can not only easily result in herd immunity but also have an excellent safety record. Moreover, they improve immunity and memory while providing long-lasting protection. This is increasing the demand for pneumococcal vaccines that aids in the prevention of pneumonia, especially in emerging economies. As pneumococcal conjugate vaccines are suitable for major age groups, their demand is increasing, which, in turn, is invigorating the market growth.
Conjugate Vaccine: Market Segmentation
A conjugated vaccine is a vaccine that is composed of weak antigens and a protein carrier molecule. It enhances the immune system and improves antigen’s immunogenicity. It also reduces asymptomatic carriage of the bacteria. Moreover, the vaccine is effective for a long period of time without resulting in any major side effects.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The major types of conjugate vaccine are:
- Monovalent Conjugate Vaccine
- Multivalent Conjugate Vaccine
The market can be broadly categorised on the basis of its disease indication into:
- Pneumococcal
- Influenza
- Diphtheria Tetanus and Pertussis (DTP)
- Meningococcal
- Others
Based on pathogen type, the market is divided into:
- Bacterial Conjugate Vaccine
- Viral Conjugate Vaccine
- Combined Conjugate Vaccine
On the basis of patient, the market is segmented into:
- Adults
- Paediatrics
The EMR report looks into the regional markets of conjugate vaccine like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Demand for Meningococcal Vaccine to Bolster the Market Growth for Conjugate Vaccine
According to the World Health Organisation (WHO), meningococcal meningitis, the bacterial form of meningitis, is prevalent in sub-Saharan Africa ranging from Senegal in the west to Ethiopia in the east. As it occurs in the region each year between December and June, various organisations and governments are rolling out vaccination drives in the region. This is increasing the use of meningococcal vaccine, hence augmenting the market growth. Moreover, the launch of various immunisation programs to generate awareness regarding the benefits of conjugate vaccines is providing further impetus to the market growth.
The exponential rise in population is expected to increase the demand for various vaccines, especially among children. The rising attempts of various non-profit organisations for approvals of conjugate vaccines are increasing its demand, hence augmenting the market growth. Increasing scientific research to develop more efficient vaccines is further invigorating the market growth. In addition, the surge of novel pathogens, which can potentially cause severe illnesses, are anticipated to propel the growth of the conjugate vaccine industry in the forecast period. Moreover, the rising demand for diphtheria, pertussis, and tetanus vaccines among children to prevent complications is also catalysing the market growth, therefore significantly contributing to the overall industry growth.
Key Industry Players in the Global Conjugate Vaccine Market
The report presents a detailed analysis of the following key players in the global conjugate vaccine market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Serum Institute of India Pvt., Ltd.
- Groupe Sanofi
- Pfizer Inc.
- Novartis AG
- Bharat Biotech Ltd.
- Others
The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2018-2022 |
| Forecast Period | 2023-2028 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Type, Disease Indication, Pathogen Type, Patient, Region |
| Breakup by Type | Monovalent Conjugate Vaccine, Multivalent Conjugate Vaccine |
| Breakup by Disease Indication | Pneumococcal, Influenza, Diphtheria Tetanus and Pertussis [DTP], Meningococcal, Others |
| Breakup by Pathogen Type | Bacterial Conjugate Vaccine, Viral Conjugate Vaccine, Combined Conjugate Vaccine |
| Breakup by Patient | Adults, Paediatrics |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Serum Institute of India Pvt., Ltd., Groupe Sanofi, Pfizer Inc., Novartis AG, Bharat Biotech Ltd., Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Conjugate Vaccine Market Analysis
8.1 Key Industry Highlights
8.2 Global Conjugate Vaccine Historical Market (2018-2022)
8.3 Global Conjugate Vaccine Market Forecast (2023-2028)
8.4 Global Conjugate Vaccine Market by Type
8.4.1 Monovalent Conjugate Vaccine
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2022)
8.4.1.3 Forecast Trend (2023-2028)
8.4.2 Multivalent Conjugate Vaccine
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2022)
8.4.2.3 Forecast Trend (2023-2028)
8.5 Global Conjugate Vaccine Market by Disease Indication
8.5.1 Pneumococcal
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2022)
8.5.1.3 Forecast Trend (2023-2028)
8.5.2 Influenza
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2022)
8.5.2.3 Forecast Trend (2023-2028)
8.5.3 Diphtheria Tetanus and Pertussis [DTP]
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2018-2022)
8.5.3.3 Forecast Trend (2023-2028)
8.5.4 Meningococcal
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2018-2022)
8.5.4.3 Forecast Trend (2023-2028)
8.5.5 Others
8.6 Global Conjugate Vaccine Market by Pathogen Type
8.6.1 Bacterial Conjugate Vaccine
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2018-2022)
8.6.1.3 Forecast Trend (2023-2028)
8.6.2 Viral Conjugate Vaccine
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2018-2022)
8.6.2.3 Forecast Trend (2023-2028)
8.6.3 Combined Conjugate Vaccine
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2018-2022)
8.6.3.3 Forecast Trend (2023-2028)
8.7 Global Conjugate Vaccine Market by Patient
8.7.1 Adults
8.7.1.1 Market Share
8.7.1.2 Historical Trend (2018-2022)
8.7.1.3 Forecast Trend (2023-2028)
8.7.2 Paediatrics
8.7.2.1 Market Share
8.7.2.2 Historical Trend (2018-2022)
8.7.2.3 Forecast Trend (2023-2028)
8.8 Global Conjugate Vaccine Market by Region
8.8.1 Market Share
8.8.1.1 North America
8.8.1.2 Europe
8.8.1.3 Asia Pacific
8.8.1.4 Latin America
8.8.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2018-2022)
9.1.2 Forecast Trend (2023-2028)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2018-2022)
9.2.2 Forecast Trend (2023-2028)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2018-2022)
9.3.2 Forecast Trend (2023-2028)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2018-2022)
9.4.2 Forecast Trend (2023-2028)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2018-2022)
9.5.2 Forecast Trend (2023-2028)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Competitive Landscape
11.1 Market Structure
11.2 Company Profiles
11.2.1 Serum Institute of India Pvt., Ltd.
11.2.1.1 Company Overview
11.2.1.2 Product Portfolio
11.2.1.3 Demographic Reach and Achievements
11.2.1.4 Certifications
11.2.2 Groupe Sanofi
11.2.2.1 Company Overview
11.2.2.2 Product Portfolio
11.2.2.3 Demographic Reach and Achievements
11.2.2.4 Certifications
11.2.3 Pfizer Inc.
11.2.3.1 Company Overview
11.2.3.2 Product Portfolio
11.2.3.3 Demographic Reach and Achievements
11.2.3.4 Certifications
11.2.4 Novartis AG
11.2.4.1 Company Overview
11.2.4.2 Product Portfolio
11.2.4.3 Demographic Reach and Achievements
11.2.4.4 Certifications
11.2.5 Bharat Biotech Ltd.
11.2.5.1 Company Overview
11.2.5.2 Product Portfolio
11.2.5.3 Demographic Reach and Achievements
11.2.5.4 Certifications
11.2.6 Others
12 Industry Events and Developments
List of Key Figures and Tables
1. Global Conjugate Vaccine Market: Key Industry Highlights, 2018 and 2028
2. Global Conjugate Vaccine Historical Market: Breakup by Type (USD Billion), 2018-2022
3. Global Conjugate Vaccine Market Forecast: Breakup by Type (USD Billion), 2023-2028
4. Global Conjugate Vaccine Historical Market: Breakup by Disease Indication (USD Billion), 2018-2022
5. Global Conjugate Vaccine Market Forecast: Breakup by Disease Indication (USD Billion), 2023-2028
6. Global Conjugate Vaccine Historical Market: Breakup by Pathogen Type (USD Billion), 2018-2022
7. Global Conjugate Vaccine Market Forecast: Breakup by Pathogen Type (USD Billion), 2023-2028
8. Global Conjugate Vaccine Historical Market: Breakup by Patient (USD Billion), 2018-2022
9. Global Conjugate Vaccine Market Forecast: Breakup by Patient (USD Billion), 2023-2028
10. Global Conjugate Vaccine Historical Market: Breakup by Region (USD Billion), 2018-2022
11. Global Conjugate Vaccine Market Forecast: Breakup by Region (USD Billion), 2023-2028
12. North America Conjugate Vaccine Historical Market: Breakup by Country (USD Billion), 2018-2022
13. North America Conjugate Vaccine Market Forecast: Breakup by Country (USD Billion), 2023-2028
14. Europe Conjugate Vaccine Historical Market: Breakup by Country (USD Billion), 2018-2022
15. Europe Conjugate Vaccine Market Forecast: Breakup by Country (USD Billion), 2023-2028
16. Asia Pacific Conjugate Vaccine Historical Market: Breakup by Country (USD Billion), 2018-2022
17. Asia Pacific Conjugate Vaccine Market Forecast: Breakup by Country (USD Billion), 2023-2028
18. Latin America Conjugate Vaccine Historical Market: Breakup by Country (USD Billion), 2018-2022
19. Latin America Conjugate Vaccine Market Forecast: Breakup by Country (USD Billion), 2023-2028
20. Middle East and Africa Conjugate Vaccine Historical Market: Breakup by Country (USD Billion), 2018-2022
21. Middle East and Africa Conjugate Vaccine Market Forecast: Breakup by Country (USD Billion), 2023-2028
22. Global Conjugate Vaccine Market Structure
Key Questions Answered in the Report
In 2021, the global conjugate vaccine market attained a value of more than USD 14.4 billion.
The market is projected to grow at a CAGR of 11% between 2023 and 2028.
The market is estimated to witness a healthy growth in the forecast period of 2023-2028 to reach over USD 27 billion by 2027.
The industry is being driven by favourable government initiatives and the rising attempts to prevent pneumonia—related deaths.
The market is expected to be driven by the increasing scientific research and the rising demand for meningococcal vaccine.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The major types of conjugate vaccine in the industry are monovalent conjugate vaccine and multivalent conjugate vaccine.
The significant disease indications in the market are pneumococcal, influenza, diphtheria tetanus and pertussis (DTP), and meningococcal, among others.
The leading pathogen types of conjugate vaccine are bacterial conjugate vaccine, viral conjugate vaccine, and combined conjugate vaccine.
The dominant patients of conjugate vaccine are adults and paediatrics.
The major players in the industry are Serum Institute of India Pvt., Ltd., Groupe Sanofi, Pfizer Inc., Novartis AG, and Bharat Biotech Ltd., among others.
Analyst Review
The global conjugate vaccine market attained a value of more than USD 14.4 billion in 2021, driven by the introduction of favourable government initiatives. Aided by the rising demand for meningococcal vaccine, the market is expected to witness a further growth in the forecast period of 2023-2028, growing at a CAGR of 11%. The market is projected to reach over USD 27 billion by 2027.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its types, the conjugate vaccine industry can be segmented into monovalent conjugate vaccine and multivalent conjugate vaccine. On the basis of disease indications, the industry is divided into pneumococcal, diphtheria tetanus and pertussis (DTP), influenza, and meningococcal, among others. By pathogen types, the market is categorised into bacterial conjugate vaccine, viral conjugate vaccine, and combined conjugate vaccine. Based on patients, the industry is bifurcated into adults and paediatrics. The major regional markets for conjugate vaccine are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Serum Institute of India Pvt., Ltd., Groupe Sanofi, Pfizer Inc., Novartis AG, and Bharat Biotech Ltd., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2799-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER